Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Operating Leases (2018 - 2025)

Summit Therapeutics (SMMT) has disclosed Operating Leases for 7 consecutive years, with $2.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases fell 35.63% year-over-year to $2.7 million, compared with a TTM value of $2.7 million through Sep 2025, down 35.63%, and an annual FY2024 reading of $3.5 million, up 4.95% over the prior year.
  • Operating Leases was $2.7 million for Q3 2025 at Summit Therapeutics, up from $2.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $5.8 million in Q1 2024 and bottomed at $351000.0 in Q1 2021.
  • Average Operating Leases over 5 years is $2.8 million, with a median of $2.8 million recorded in 2022.
  • The sharpest move saw Operating Leases soared 2154.67% in 2021, then tumbled 51.47% in 2025.
  • Year by year, Operating Leases stood at $1.7 million in 2021, then skyrocketed by 63.39% to $2.8 million in 2022, then grew by 19.07% to $3.3 million in 2023, then increased by 4.95% to $3.5 million in 2024, then dropped by 21.58% to $2.7 million in 2025.
  • Business Quant data shows Operating Leases for SMMT at $2.7 million in Q3 2025, $2.4 million in Q2 2025, and $2.9 million in Q1 2025.